Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
(Adnkronos) – The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ — Pharming
